We established ReSViNET in 2014, and since 2018, ReSViNET has been a foundation — a financially and otherwise independent regulated entity. Julius Clinical works closely with ReSViNET to provide operational support to RSV clinical trials and observational studies. Our operational team has extensive experience in coordinating these studies, and ReSViNET has access to sites in countries across the globe, providing fast recruitment and high retention rates.
Webinar: Progress in RSV Vaccines and Monoclonal Antibodies
On May 10, our partner ReSViNET presented the webinar: Progress in RSV Vaccines and Monoclonal AntibodiesIn this webinar, Professor Barney Graham, MD, PhD, shared his views on the lanscape of RSV therapeutics. The webinar was hosted by Prof. D...